Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04946721 · ClinicalTrials.gov registry record
2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD
A clinical trial of Dry Eye Disease and oGVHD, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT04946721: Recruiting study of Dry Eye Disease and oGVHD, sponsored by University of Maryland, Baltimore.
NCT04946721 is a study of Dry Eye Disease and oGVHD that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 150 participants, below the 250-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04946721, a study of Dry Eye Disease and oGVHD, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluate and study the immunologic changes to the ocular surface in cancer patients.
Primary Outcome
Number of patients with the risks and markers who have developed the eye diseases during the study
Conditions Studied
Interventions
- DIAGNOSTIC_TEST The standard care exam and biological specimens' collection
Study Locations (1)
Maryland
- Geenebaum Cancer Center, University of Maryland Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2027-12-31 |
What NCT04946721 shows while recruiting
NCT04946721 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 250-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (40% lower).
The record links to 2 conditions, with Dry Eye Disease appearing as the primary indexed condition, and to 1 intervention - of which The standard care exam and biological specimens' collection is the first listed.
NCT04946721 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04946721 about?
NCT04946721 is a clinical study titled "2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD". Evaluate and study the immunologic changes to the ocular surface in cancer patients.
What is the current status of trial NCT04946721?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2022-04-27. Estimated completion is 2027-12-31.
What conditions does trial NCT04946721 study?
This clinical trial studies the following conditions: Dry Eye Disease, oGVHD.
What interventions are being tested in trial NCT04946721?
The interventions under investigation include: The standard care exam and biological specimens' collection (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04946721?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04946721 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04946721's enrollment target sits among peer trials
150 20th of 33 higher than 14 of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
RECRUITING · Phase 4
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
ACTIVE NOT RECRUITING · NA
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI